Archive
Home / Media Centre / Archive
Here you can find the archive of all Press Releases prior to 2022
Filter by date:
Showing 1107 press releases before 2022
-
Tagrisso approved in China as first-in-class treatment for EGFR T790M mutation-positive metastatic non-small cell lung cancer
-
AstraZeneca’s CVD-REAL study shows SGLT-2 inhibitors significantly reduced death and hospitalisations for heart failure versus other type-2 diabetes medicines
-
AstraZeneca and Circassia enter strategic collaboration in respiratory disease
-
AstraZeneca receives Complete Response Letter from US FDA for ZS-9 (sodium zirconium cyclosilicate) for hyperkalaemia
-
Lynparza Phase III SOLO-2 data demonstrate progression-free survival benefit in BRCA-mutated ovarian cancer as maintenance therapy
-
MedImmune and Sanofi Pasteur form alliance to develop and commercialise potential next-generation respiratory syncytial virus antibody MEDI8897
-
FDA approves once-daily Qtern (dapagliflozin and saxagliptin) tablets for adults with type-2 diabetes
-
ZS-9 (sodium zirconium cyclosilicate) receives positive CHMP opinion for the treatment of hyperkalaemia
-
AstraZeneca enters agreement with TerSera Therapeutics for Zoladex in the US and Canada
-
Updated durvalumab monotherapy data confirm results in urothelial bladder cancer
Latest articles and press releases
All of our latest press releases and articles are available to explore
